Clinical Trial Update: A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for a Phase II/III study of Linperlisib plus CHOP versus CHOP in newly diagnosed peripheral T-cell lymphoma, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Linperlisib (linperlisib)

Snippet

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Conditions: Peripheral T Cell Lymphoma | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING